Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.23, Zacks reports. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 122.00%.
Vivos Therapeutics Stock Down 16.1%
VVOS traded down $0.02 during trading on Monday, reaching $0.08. 4,970,300 shares of the company’s stock were exchanged, compared to its average volume of 4,962,193. Vivos Therapeutics has a fifty-two week low of $0.07 and a fifty-two week high of $2.69. The business has a 50 day moving average price of $0.14 and a 200 day moving average price of $0.66. The company has a market capitalization of $1.65 million, a P/E ratio of -0.04 and a beta of 6.37.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Vivos Therapeutics presently has an average rating of “Hold” and an average target price of $2.80.
Get Our Latest Research Report on Vivos Therapeutics
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
Read More
- Five stocks we like better than Vivos Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
